Breaking News

OsoBio Names Quality VP

May 9, 2013

Lee oversaw validation, quality for Amgen expansion

David M. Lee has been appointed vice president of quality at OsoBio. Mr. Lee is responsible for overseeing all quality-related functions to ensure continued compliance with cGMP, including quality systems, quality control and manufacturing quality assurance. Mr. Lee has more than 20 years of professional experience managing quality operations and API and sterile manufacturing.
 
Prior to joining the company, he served as director of validation and quality at Amgen, where he managed all validation activities for a $1.2-billion site expansion. He also managed production operations for two of the company’s flagship drugs, Neupogen and Neulasta.
 
“David’s knowledge and expertise in quality operations will support OsoBio’s ongoing ability to deliver exceptional sterile pharmaceutical manufacturing products and service,” said Milton Boyer, president of OsoBio. “David has already proven to be a great asset to the OsoBio team and the clients we serve.”

Related Compliance:

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments